Total buying$00 buys
ARTV
Artiva Biotherapeutics, Inc.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 09/19 to 10/19.
How these metrics are calculated
Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total selling$726k5 sells
Net open-market−$726kBuying minus selling
Active insiders4Distinct reporting owners
Insider activity report
Calendar-month buckets within the selected date range
Latest filing: Oct 07, 2026
Open-market transaction mix · 5 transactions in the selected period
Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.
View exact monthly counts and disclosed values
| Month | Buys | Sells | Awards (A) | Buy value | Sell value | Net P/S value |
|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | 0 | $0 | $0 | $0 |
| Oct 2026 | 0 | 5 | 0 | $0 | $726k | -$726k |
Distinct insiders active
Reporting-owner CIKs by month · peak Oct 2026 (4)Sep 2026Oct 2026
Largest insider activity
By absolute net disclosed value · current transaction page- AF-$590.7k
- HC-$70.7k
- BJ-$57.2k
- BS-$7.5k
ARTV transaction history
Newest filings · 20 transactions per pageLatest insider transactions
Form 4 filings from last month.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ARTVArtiva Biotherapeutics, Inc. | Aslan FredCEO | S · sale10b5-1 detectedSEC filing ↗ | -$168kView disclosure → | |
ARTVArtiva Biotherapeutics, Inc. | Horan ChristopherCTOO | S · saleSEC filing ↗ | -$70.6kView disclosure → | |
ARTVArtiva Biotherapeutics, Inc. | Bush JenniferCOO · CLO · CO | S · saleSEC filing ↗ | -$57.2kView disclosure → | |
ARTVArtiva Biotherapeutics, Inc. | Banerjee SubhashisCMO | S · saleSEC filing ↗ | -$7.51kView disclosure → | |
ARTVArtiva Biotherapeutics, Inc. | Aslan FredCEO | S · saleSEC filing ↗ | -$421kView disclosure → |
Filing-only signals
Deterministic matches in the selected period
Filing detail checks
Secondary metrics for the selected periodTransaction codes
By Form 4 transaction code in selected period5transactionstxns
- S · Open-market sells · dominant5 · 100%
Activity by reported role
A joint filing can contribute to multiple rolesChief executive officer2
CLO1
CMO1
CO1
COO1
CTOO1
Reported Holdings After
Separated by insider, security, and ownership type
Aslan FredCommon Stock · Direct
1,519,606Oct 06, 2026
Banerjee SubhashisCommon Stock · Direct
169,848Oct 05, 2026
Bush JenniferCommon Stock · Direct
366,159Oct 05, 2026
Horan ChristopherCommon Stock · Direct
312,744Oct 05, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells redSep 19 → Oct 19
LessMore
Artiva Biotherapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Artiva Biotherapeutics, Inc.?
Aslan Fred, Horan Christopher, Bush Jennifer, Banerjee Subhashis.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Aslan Fred reported a sale on Oct 06, 2026 valued at $168k. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $726,145.62. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.